NEW YORK, April 09, 2014 — (Techsonian) – Rigel Pharmaceuticals, (NASDAQ:RIGL) declared that the American Journal of Physiology has published current research results with its orally-bioavailable AMPK activator, R118. The publication, entitled “Exercise performance and peripheral vascular insufficiency improve with AMPK activation provides strong preclinical evidence that R118 may be useful in treating peripheral artery disease (PAD), a chronic and progressive vascular disease effecting nearly 5 percent of the population over the age of 50, and connected metabolic disorders.
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) recently declined -4.58%, while trading on 1.41 million shares at the price of $3.33. If we look at its trading history of the past 52 weeks, the share price suffered a low of $2.31 and was moved to its maximum level of $5.00. The stock changed hands in a range of $3.27 to $3.58, bringing its market capitalization at about $291.46 million.
Has RIGL Found The Bottom and Ready To Move Up? Find Out Here
Hemispherx Biopharma, (NYSEMKT: HEB) announced the peer-reviewed publication titled “Discordant Biological and Toxicological Species Responses to TLR-3 Activation” in the current issue of the American Journal of Pathology Vol. 184 (pages 1062-1072), 2014.
Hemispherx BioPharma, Inc (NYSEMKT:HEB) declined -4.05% recently, in the current trading session, at $0.360 with a total volume of 1.37 million shares. The stock, on average, trades on a volume of 1.90 million shares. It floated in a range of $0.36 to $0.38 during the recent trading session, with a beta value of 1.52. Its market capitalization now moved to about $64.62 million. In the past 52 weeks, the share price has not declined below $0.19 or above $0.55.
Has HEB Found The Bottom And Ready To Gain Momentum? Find Out Here
Pixelworks, (NASDAQ: PXLW) declared that Mr. David J. Tupman has been appointed to the Company’s board of directors.
Pixelworks, Inc. (NASDAQ:PXLW) recently declined -5.26% and was moving within a range of $5.10-$5.57, its current trading price is $5.22. The stock is moving up till now with a total volume of 1.33 million shares, versus an average volume of 2.89 million shares. The share price hit its 52-week low of $2.11 and $9.05 was the best price.
Why Should Investors Buy PXLW After the Recent Fall? Just Go Here and Find Out
Body Central, (NASDAQ:BODY) announced financial results for the fourth quarter of 2013. Highlights for the thirteen weeks ended December 28, 2013 shows that Net revenues for the quarter decreased 18.3% to $66.2 million, compared to $81.0 million for the fourth quarter of 2012.
Body Central Corp (NASDAQ:BODY) declined -5.69% in its current trading activity, bringing its market capitalization around $19.31 million. The total number of shares that changed hands during the current session up till now was 1.03 million shares, as compared to average trading volume of 1.15 million shares. The share price after opening at $1.24 made a high of $1.26 and hovered above $1.15, while its recent trading price was $1.16.
Will BODY Get Buyers Even After The Recent Decline? Find Out Here